Lakewood, Colo., April 04, 2018 -- – Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2018, to shareholders of record at the close of business on May 31, 2018.
About Mesa Laboratories, Inc.
Mesa is a global technology innovator committed to solving some of the most critical quality control and analytical challenges in the pharmaceutical, healthcare, industrial safety, environmental and food & beverage industries. Mesa offers products and services through four divisions (Sterilization and Disinfection Control, Instruments, Cold Chain Monitoring and Cold Chain Packaging) which help its customers ensure product integrity, increase patient and worker safety, and design innovative solutions that improve the quality of life throughout the world.
Forward Looking Statements
This press release may contain information that constitutes "forward-looking statements." Generally, the words "believe," “estimate,” "expect," "project," “anticipate,” “intend,” "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenue growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. These risks and uncertainties include, but are not limited to, those described in our Annual Report on Form 10-K for the year ended March 31, 2017, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.
For more information about the Company, please visit its website at www.mesalabs.com
CONTACT: Gary Owens.; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc., +1-303-987-8000


Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners
Apple Restores Telegram to App Store After Content Policy Violation
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 



